GB3 as a Novel Therapeutic Target in Neuroblastoma's Alternative Vasculature through Stiffness Modeling
- Autores: Aránzazu Villasante Bermejo, Josep Corominas, Clara Alcon Franch, Andrea Garcia, Jaume Mora
- Localización: CASEIB 2023. Libro de Actas del XLI Congreso Anual de la Sociedad Española de Ingeniería Biomédica: Contribuyendo a la salud basada en valor / coord. por Joaquín Roca González, Dolores Ojados González, Juan Suardíaz Muro, 2023, ISBN 978-84-17853-76-1, págs. 622-625
- Idioma: inglés
- Enlaces
-
Resumen
Neuroblastoma (NB) is a childhood cancer from sympathetic nervous system cells. NB exhibits cellular heterogeneity, with N, S, and I-type cells displaying distinct tumorigenic potentials. NB is highly vascularized, and blood vessels can form through various mechanisms, including endothelial transdifferentiation, leading to the development of tumor-derived endothelial cells (TECs) associated with chemoresistance. We lack specific biomarkers for TECs, relying mainly on general endothelial- expressed proteins like CD31 or stemness-related markers, which are crucial for the survival of healthy cells. Therefore, identifying new TEC biomarkers is vital for effective NB therapies. A stiffness-based platform simulating human arterial and venous stiffness was developed to study neuroblastoma TECs in vitro. N and I-type cells cultured on arterial-like stiffness transdifferentiated into TECs, while S-type cells did not. We employed TECs derived from N-type NB cells as ...
